No Data
No Data
Express News | TScan Therapeutics Inc: Timothy Barberich Retires as Chair & Stephen Biggar Assumes Role of Chair
Express News | TScan Therapeutics Announces Updates to Its Board of Directors
The Analyst Landscape: 7 Takes On TScan Therapeutics
Analysts' ratings for TScan Therapeutics (NASDAQ:TCRX) over the last quarter vary from bullish to bearish, as provided by 7 analysts.The following table summarizes their recent ratings, shedding light
Buy Rating Affirmed for TScan Therapeutics Amidst Promising Clinical Advancements
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T)
Express News | TScan Therapeutics Says FDA Granted Regenerative Medicine Advanced Therapy Designation To TSC-100 And TSC-101
No Data